Repeat biopsy one year following the second course of Rituximab demonstrated ongoing active primary membranous nephropathy with strong PLA2R staining in peripheral capillary loops, with 20% interstitial fibrosis and tubular atrophy (IFTA). The gene discussed is PLA2R1; the disease is membranous glomerulonephritis.